In this regard, alternative treatments have been studied and new drugs have been developed, such as those agents classified as Selective Estrogen Receptor Modulators (SERMs), because they act, according to the target tissue, as estrogen agonists and antagonists, e.g., inhibiting bone resorption and breast cancer growth [1,2,8]. This evidence concerns the gene ESR1 and breast carcinoma.